CYP2C19 Genotype and Phenotype Determined with Omeprazole in Patients with Acid-Related Disorders with and without Helicobacter pylori Infection

References

• Regårdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986;21 Suppl 118:99–104.
   Google Scholar
• Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 Suppl 166:33–40.
   PubMedGoogle Scholar
• Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415–6.
   PubMed Web of Science ®Google Scholar
• Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:32–7.
   PubMedGoogle Scholar
• Sohn DR, Kobayashi K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from Oriental population. J Pharmacol Exp Ther 1992;262: 1195–202.
   Google Scholar
• Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402–8.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388–97.
   Google Scholar
• Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 657–85.
   Google Scholar
• Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population? Clin Pharmacol Ther 1993;53:608–10.
   PubMed Web of Science ®Google Scholar
• Ward SA, Helsby NA, Skjelbo E, Brasen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 1991;31:689–92.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419–22.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594–8.
   PubMed Web of Science ®Google Scholar
• Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5: 358–63.
   Google Scholar
• Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, et al. Inter phenotype differences in disposition and effect on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39: 511–8.
   Google Scholar
• Roh H-K, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in Korean population. Pharmacogenetics 1996;6: 547–51.
   Google Scholar
• Labenz J, Tillenburg B, Peitz U, Idström J-P, Verdú EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in the patients with duodenal ulcer. Gastroenterology 1996;110:725–32.
   Google Scholar
• Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347–56.
   PubMed Web of Science ®Google Scholar
• Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalysed by CYP2C19 in Swedish Caucasian subjects. Clin Pharmacol Ther 1997;62:129–37.
   PubMed Web of Science ®Google Scholar
• Befrits R, Granström M, Rylander M, Rubio C. Helicobacter pylori in 205 consecutive endoscopy patients. Scand J Infect Dis 1993;25:185–91.
   PubMed Web of Science ®Google Scholar
• Granström M, Tindberg Y, Blennow M. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. J Clin Microbiol 1997;35: 468–70.
   Google Scholar
• Dahl-Puustinen ML, Alm C, Bertilsson L, Christenson I, Ostman J, Thunberg E, et al. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. Br J Pharmacol 1990;30:476–80.
   Google Scholar
• Rost KL, Brockmoller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995;23:268–77.
   PubMedGoogle Scholar
• Verdú EF, Armstrong D, Idström J-P, Labenz J, Stolte M, Börsch G, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gasteroenterol 1996;31: 1151–6.
   PubMed Web of Science ®Google Scholar
• Masini E, Bechi P, Dei R, Di Bello MG, Bani Sacchi T. Helicobacter pylori potentiates histamine release from rat serosal mast cells induced by bile acids. Dig Dis Sci 1994; 39:1493–500.
   Google Scholar
• Calam J, Goldner EH, Walsh JH, Soll AH. Mononuclear cells, but not H. pylori, release gastrin from cultured G-cells via diffusable factors [abstract]. Gut 1993;34:S3 W11.
   Google Scholar
• Helander HF, Fryklund, Walmark B. Structure and function of isolated gastric glands [abstract]. Gastroenterology 1987;92:A1431.
   Google Scholar